Among lung cancer patients with EGFR sensitizing mutations and on therapy, CSF sequencing demonstrated the emergence of gatekeeper mutations associated with acquired resistance, including EGFR p.T790M, p.C797S, p.L792H, p.L718Q, p.L718V and p.G724S. Here, EGFR is linked to lung carcinoma.